Search

Objective: To observe the efficacy and side effects of transarterial chemoembolization (TACE) combined with sorafenib for advanced hepatocellular carcinoma (HCC)., Methods: Forty patients with HCC were treated with sorafenib (400 mg bid) after TACE. The efficacy was evaluated according to RECIST 1.1 criteria, and side effects were assessed by NCI CTC 3.0 criteria., Results: Among the forty cases, one case achieved complete remission (CR), seven cases achieved partial remission (PR), nineteen cases achieved stable disease (SD) and thirteen cases had progressive disease (PD). The disease control rate (DCR) was 67.5%. The overall survival time was 1 - 18 months, and 1-year survival rate was 54.0%. The major adverse events were hand-foot skin reaction, diarrhea and thrombocytopenia., Conclusion: The combined therapy of TACE and sorafenib is effective and well tolerated for advanced HCC.

Objective: To evaluate the efficacy and analyze the prognostic factors of sorafenib treatment in patient with unresectable primary hepatocellular carcinoma (HCC)., Methods: During the period from December 2005 to March 2009, 50 patients with unresectable primary HCC of Child-Pugh status A were treated with sorafenib (400 mg, Bid). The tumor response was evaluated with CT or MRI imaging every 6 - 8 weeks according to the RECIST criteria. The overall survival (OS) and time to progression (TTP) were defined as the time from administration of sorafenib to the death or the last follow up and were evaluated by Kaplan-Meier method., Results: There was no PR or CR, but 28 patients (56.0%) achieved stable disease. The median follow up time was 15 months with a median OS of 14 months and median TTP of 4 months. The common adverse events were dermal reaction (68.0%, 34/50), diarrhea (52.0%, 26/50), hypertension (4.0%, 2/50), hair loss (14.0%, 7/50), myelosuppression (16.0%, 8/50), and liver dysfunction (20.0%, 10/50). However, most of the drug-related adverse events were grade I-II and reversible. The patients with lower tumor burden and without distant metastasis had better prognosis., Conclusion: Soafenib is effective for unresectable primary HCC with tolerable toxicity. Tumor stage is a predominant prognostic factor.

Objective: To evaluate the safety and efficacy of the combination of transcatheter arterial chemoembolization (TACE) and sorafenib in treatment of hepatocellular carcinoma (HCC) with lung metastasis., Methods: Thirty HCC patients with lung metastasis were treated by the combination of TACE and sorafenib between Oct 2006 and May 2008, including 27 men and 3 women. The age of the patients ranged 32 to 73 years old. Sorafenib was administrated orally at 400 mg, twice daily (the less tolerant patients received 200 mg, bid.), if there was no counterindication, at 3 - 4 weeks after TACE, with every 4 weeks as a course of treatment. The efficacy was evaluated at the end of every course of treatment., Results: The metastatic lesions in the lung were diminished in 6 cases and stable diseases achieved in 8 cases. The primary liver tumors were stable in 22 cases, including 10 cases achieved by TACE before sorafenib treatment. Eight cases had slightly progressed liver tumors and were treated with 1 - 3 times of TACE in combination with sorafenib. Side effects included skin lesions in 7 cases, hair loss in 6 cases, fatigue in 18 cases, diarrhea in 6 cases, anemia and bone marrow suppression in 5 cases, high blood pressure in 2 cases, and gastrointestinal bleeding in 1 case., Conclusion: The combination of TACE and sorafenib can be used as an effective treatment for hepatocellular carcinoma patients with lung metastasis, which may stabilize the disease in some patients.

Objective: To observe the efficacy and safety of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma (HCC)., Methods: Thirty-eight patients with advanced HCC of Child-Pugh status A or B were included in this study. Patients received orally administered sorafenib at a dose of 400 mg twice a day on a continuous schedule. Adverse events were documented. The efficacy and safety were evaluated every four to six weeks., Results: During the treatment, partial response (PR) was observed in 1 patient (2.6%), minor response (MR) in 5 (13.2%), stable disease (SD) in 16 (42.1%), and progressive disease (PD) in 16 (42.1%), respectively. The median oral administration time of sorafenib was 180 days (range, 15-550 d), and the mean overall survival was 370 days (range, 42-562 days). The median response duration was 169 days (range, 42-426 days). The mean overall survival of 22 patients with controlled disease (PR + MR + SD) was 428 days (95% CI 330-526 days). The most frequent adverse events were dermal reaction (27 cases, 71.1%), gastrointestinal reaction (25 cases, 65.8%), and constitutional symptoms (14 cases, 36.8%). Most of the drug related adverse events were mild and easily to manage and reversible., Conclusion: Sorafenib monotherapy is effective and tolerable in a part of Chinese patients with advanced hepatocellular carcinoma and liver function of Child-Pugh A or B, and may prolong their survival.

Objective: To observe the effect of sodium dodecylbenzene sulfonate (SDBS) in killing Demodex in vitro and in the treatment of demodicidosis., Methods: (1) The experiment of in vitro killing Demodex with 1% and 2% SDBS was conducted. (2) A clinical trial was carried out to evaluate the therapeutic effect in the treatment of demodicidosis with 2% SDBS and 2% metronidazole emulsion. Patients with demodicidosis were randomly divided into trial and control groups (31 cases each). They were treated with 2% SDBS ointment and 2% metronidazole ointment twice a day in the early morning and evening respectively for eight weeks consecutively. Inflammatory lesions of face, Demodex infestation and scores of erythema were measured to evaluate the effect before and after treatment. (3) Follow-up was carried out for two months to evaluate the effect and side effects after 8 weeks' treatment., Results: (1) 2% SDBS killed all Demodex in vitro after 5 h, there was significant difference between the 2% SDBS and 2% metronidazole (69.4%), or between SDBS and peanut oil (9.1%) (P < 0.05). There was no significant difference in killing Demodex folliculorum and Demodex brevis with 2% SDBS. (2) Clinical observation showed that there was a significant difference in facial inflammatory lesions, Demodex infestation and scores of erythema before and after treatment with 2% SDBS (P < 0.05). The effective rate was 87.1%, 65.5% in 2% SDBS group and 2% metronidazole group respectively, with a significant difference between the two groups (P < 0.05). Follow up showed same results. (3) A slight burning sensation was the only side-effect in 3 cases with 2% SDBS ointment., Conclusion: Sodium dodecylbenzene sulfonate has the effect of in vitro killing Demodex and is highly effective in the treatment of demodicidosis.